Authors: Hidestrand, M Oscarson, M Salonen, JS Nyman, L Pelkonen, O Turpeinen, M Ingelman-Sundberg, M

Citation: M. Hidestrand et al., CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes, DRUG META D, 29(11), 2001, pp. 1480-1484

Authors: Kaivosaari, S Salonen, JS Mortensen, J Taskinen, J

Citation: S. Kaivosaari et al., High-performance liquid chromatographic method combining radiochemical andultraviolet detection for determination of low activities of uridine 5 '-diphosphate-glucuronosyltransferase, ANALYT BIOC, 292(2), 2001, pp. 178-187

Authors: Taavitsainen, P Anttila, M Nyman, L Karnani, H Salonen, JS Pelkonen, O

Citation: P. Taavitsainen et al., Selegiline metabolism and cytochrome P450 enzymes: In vitro study in humanliver microsomes, PHARM TOX, 86(5), 2000, pp. 215-221

Authors: Soveri, T Sankari, S Salonen, JS Nieminen, M

Citation: T. Soveri et al., Effects of immobilization with medetomidine and reversal with atipamezole on blood chemistry of semi-domesticated reindeer (Rangifer tarandus tarandus L.) in autumn and late winter, ACT VET SC, 40(4), 1999, pp. 335-349

Authors: Haapalinna, A MacDonald, E Viitamaa, T Salonen, JS Sirvio, J Virtanen, R

Citation: A. Haapalinna et al., Comparison of the effects of acute and subchronic administration of atipamezole on reaction to novelty and active avoidance learning in rats, N-S ARCH PH, 359(3), 1999, pp. 194-203